Log in

OTCMKTS:ATMSArtemis Therapeutics Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $0.04
50-Day Range
MA: $0.09
52-Week Range
Now: $0.04
Volume20 shs
Average Volume1,866 shs
Market Capitalization$180,765.00
P/E RatioN/A
Dividend YieldN/A
Artemis Therapeutics Inc., a biopharmaceutical company, engages in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company's lead product candidate is Artemisone, an orally-administered 10-alpha-amino artemisinin derivative with antiviral and antiparasitic properties. It focuses on advancing Artemisone as an antiparasitic treatment for patients infected with Plasmodium falciparum; and as an antiviral agent to address unmet clinical needs in immunocompromised patients infected with human cytomegalovirus and other viral or infectious diseases. The company has license agreement with Hadasit Medical Research Services and Development Ltd., Hadassah Medical Organization, and Hong Kong University of Science and Technology R and D Corporation Limited for the development of Artemisone. Artemis Therapeutics Inc. was incorporated in 1997 and is based in New York, New York. Artemis Therapeutics Inc. is a subsidiary of Tonak Ltd.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous chemical products
Current SymbolOTCMKTS:ATMS



Sales & Book Value

Annual SalesN/A
Book Value($0.05) per share


Net Income$-120,000.00


Market Cap$180,765.00
Next Earnings DateN/A
OptionableNot Optionable

Receive ATMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATMS and its competitors with MarketBeat's FREE daily newsletter.

Artemis Therapeutics (OTCMKTS:ATMS) Frequently Asked Questions

How has Artemis Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Artemis Therapeutics' stock was trading at $0.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ATMS stock has decreased by 64.9% and is now trading at $0.0351. View which stocks have been most impacted by Coronavirus.

Has Artemis Therapeutics been receiving favorable news coverage?

News coverage about ATMS stock has trended very positive this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Artemis Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutArtemis Therapeutics.

Who are some of Artemis Therapeutics' key competitors?

Who are Artemis Therapeutics' key executives?

Artemis Therapeutics' management team includes the following people:
  • Mr. Chanan Morris, Chief Financial Officer (Age 53)
  • Prof. Dana Wolf, Chief Scientific Officer (Age 62)
  • Mr. Brian M. Culley, Chief Exec. Officer (Age 48)

What is Artemis Therapeutics' stock symbol?

Artemis Therapeutics trades on the OTCMKTS under the ticker symbol "ATMS."

How do I buy shares of Artemis Therapeutics?

Shares of ATMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Artemis Therapeutics' stock price today?

One share of ATMS stock can currently be purchased for approximately $0.04.

How big of a company is Artemis Therapeutics?

Artemis Therapeutics has a market capitalization of $180,765.00.

What is Artemis Therapeutics' official website?

The official website for Artemis Therapeutics is www.artemis-therapeutics.com.

How can I contact Artemis Therapeutics?

Artemis Therapeutics' mailing address is 18 EAST 16TH STREET SUITE 307, NEW YORK NY, 10003. The company can be reached via phone at 646-233-1454 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.